secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0001628280-22-021347
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Biotherapeutics closes underwritten public offering of 8.625M shares at $20, net proceeds ~$161.7M
--------------------------------------------------------------------------------

- Sold 7.5M shares plus full exercise of over-allotment of 1.125M shares at $20 per share.
- Net proceeds approximately $161.7M after underwriting discounts and expenses.
- Proceeds to fund development, approval, commercial launch for ZORYVE and general corporate purposes.
- Underwriters include Morgan Stanley, Cowen, Guggenheim Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022021347/0001628280-22-021347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022021347/arqt-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer